Published in J Dent Res on April 10, 2012
Genetics of cleft lip and cleft palate. Am J Med Genet C Semin Med Genet (2013) 1.38
Interaction between IRF6 and TGFA genes contribute to the risk of nonsyndromic cleft lip/palate. PLoS One (2012) 0.91
Spectrum of Dental Phenotypes in Nonsyndromic Orofacial Clefting. J Dent Res (2015) 0.79
Natal and neonatal teeth among cleft lip and palate infants. Natl J Maxillofac Surg (2013) 0.78
Tooth agenesis and orofacial clefting: genetic brothers in arms? Hum Genet (2016) 0.75
E-cigarette aerosol exposure can cause craniofacial defects in Xenopus laevis embryos and mammalian neural crest cells. PLoS One (2017) 0.75
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int (1999) 2.87
Complete sequencing shows a role for MSX1 in non-syndromic cleft lip and palate. J Med Genet (2003) 2.72
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia (2010) 2.35
Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia (2011) 2.28
Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest (2001) 2.20
Taste genes associated with dental caries. J Dent Res (2010) 2.17
Diabetes and hypertension. Australian Diabetes Society position statement. Med J Aust (1995) 2.14
Genome-wide association scan for childhood caries implicates novel genes. J Dent Res (2011) 2.05
Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia (2011) 1.90
Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation (1998) 1.87
ENAM mutations in autosomal-dominant amelogenesis imperfecta. J Dent Res (2005) 1.83
Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis (2005) 1.71
Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol (2011) 1.71
Reduced bone mass in daughters of women with osteoporosis. N Engl J Med (1989) 1.70
PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int (2001) 1.69
Developmental expression of ACE2 in the SHR kidney: a role in hypertension? Kidney Int (2006) 1.68
Possible association of amelogenin to high caries experience in a Guatemalan-Mayan population. Caries Res (2007) 1.67
Enamel formation genes are associated with high caries experience in Turkish children. Caries Res (2008) 1.57
Tuftelin, mutans streptococci, and dental caries susceptibility. J Dent Res (2005) 1.57
Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. Hypertension (2000) 1.56
Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia (2003) 1.55
Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes. Diabetologia (2011) 1.51
Defining subphenotypes for oral clefts based on dental development. J Dent Res (2007) 1.51
The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia (1995) 1.46
Limitations of cognitive status exams: a case-based discussion. Psychiatry (1996) 1.43
Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes (1994) 1.40
Letter: Death of a pioneer. Vet Rec (1974) 1.39
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes. Med J Aust (2001) 1.39
Renal expression of transforming growth factor-beta inducible gene-h3 (beta ig-h3) in normal and diabetic rats. Kidney Int (1998) 1.36
Maternal and fetal variation in genes of cholesterol metabolism is associated with preterm delivery. J Perinatol (2007) 1.36
The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst (2000) 1.35
Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension (2000) 1.35
Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J Hepatol (2001) 1.35
Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes (2007) 1.29
Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest (1998) 1.29
Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies. Breast Cancer Res Treat (2012) 1.28
MSX1 and TGFB3 contribute to clefting in South America. J Dent Res (2003) 1.28
Targeted scan of fifteen regions for nonsyndromic cleft lip and palate in Filipino families. Am J Med Genet A (2004) 1.24
Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia (1997) 1.24
Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut (2005) 1.23
The emerging role of ACE2 in physiology and disease. J Pathol (2007) 1.22
Application of American College of Surgeons' field triage guidelines by pre-hospital personnel. J Am Coll Surg (1995) 1.21
Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia (2001) 1.21
A pH-sensitive fluor, CypHer 5, used to monitor agonist-induced G protein-coupled receptor internalization in live cells. Biotechniques (2002) 1.20
Dietary fiber and breast cancer risk: a systematic review and meta-analysis of prospective studies. Ann Oncol (2012) 1.20
Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Am J Pathol (1999) 1.19
LAMB3 mutations causing autosomal-dominant amelogenesis imperfecta. J Dent Res (2013) 1.17
Contributions of PTCH gene variants to isolated cleft lip and palate. Cleft Palate Craniofac J (2006) 1.16
MMP20 hemopexin domain mutation in amelogenesis imperfecta. J Dent Res (2010) 1.16
Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int (1997) 1.16
Diabetic renal disease: from recent studies to improved clinical practice. Diabet Med (2004) 1.15
The antimicrobial peptide DEFB1 is associated with caries. J Dent Res (2010) 1.13
Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products. J Clin Invest (1997) 1.12
Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract (2008) 1.12
[Hemoptysis and the adult respiratory distress syndrome as the causes of death in leptospirosis. Changes in the clinical and anatomicopathological patterns]. Rev Soc Bras Med Trop (1993) 1.11
The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets (2005) 1.09
Anaemia in diabetes: Is there a rationale to TREAT? Diabetologia (2006) 1.08
A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int (1998) 1.08
Identification and characterization of both the cytosolic and particulate forms of cyclic GMP-stimulated cyclic AMP phosphodiesterase from rat liver. Biochem J (1986) 1.06
The insulin- and glucagon-stimulated 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase from rat liver. Purification, characterization and inhibitor sensitivity. Biochem J (1987) 1.05
Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia (2007) 1.05
Novel KLK4 and MMP20 mutations discovered by whole-exome sequencing. J Dent Res (2013) 1.04
Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int (2000) 1.03
Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia (2000) 1.03
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int Suppl (1999) 1.00
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia (2001) 1.00
Diabetic nephropathy: from mechanisms to rational therapies. Minerva Med (2006) 1.00
Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. Diabetes (1994) 1.00
Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab (2000) 0.99
Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia (2007) 0.99
Disseminated American muco-cutaneous leishmaniasis caused by Leishmania braziliensis braziliensis in a patient with AIDS: a case report. Mem Inst Oswaldo Cruz (1994) 0.98
Potent blockers of the monocarboxylate transporter MCT1: novel immunomodulatory compounds. Bioorg Med Chem Lett (2006) 0.98
Genetic evidence for the role of loci at 19q13 in cleft lip and palate. J Med Genet (2006) 0.98
The many faces of the genetics contribution to temporomandibular joint disorder. Orthod Craniofac Res (2008) 0.98
Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia (2001) 0.97
Candidate gene strategy reveals ENAM mutations. J Dent Res (2009) 0.97
Microalbuminuria: prognostic and therapeutic implications in diabetes mellitus. Diabet Med (1994) 0.96
Increased epidermal growth factor in experimental diabetes related kidney growth in rats. Diabetologia (1997) 0.95
Cellular mechanisms of diabetic vascular hypertrophy. Microvasc Res (1999) 0.95
Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney. Nephrol Dial Transplant (1998) 0.95
Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. Circ Res (2000) 0.95
Cleft lip with or without cleft palate and dermatoglyphic asymmetry: evaluation of a Chinese population. Orthod Craniofac Res (2002) 0.94
Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl (2007) 0.94
A genome-wide linkage scan for cleft lip and cleft palate identifies a novel locus on 8p11-23. Am J Med Genet A (2007) 0.94
Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia (2010) 0.93
Increased risk of cardiovascular disease in Type 1 diabetes: arterial exposure to remnant lipoproteins leads to enhanced deposition of cholesterol and binding to glycated extracellular matrix proteoglycans. Diabet Med (2011) 0.93
Case/control family study of autonomic nervous system dysfunction in idiopathic congenital central hypoventilation syndrome. Am J Med Genet (2001) 0.93
ACE inhibition salvages the visual loss caused by diabetes. Diabetologia (2003) 0.93
Role of angiotensin II in tubulointerstitial injury. Semin Nephrol (2001) 0.93
Axis inhibition protein 2 (AXIN2) polymorphisms and tooth agenesis. Arch Oral Biol (2008) 0.92
Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes (1998) 0.91
Novel WDR72 mutation and cytoplasmic localization. J Dent Res (2010) 0.91